Relationship between adiponectin, inflammatory markers and obesity in Type 2 diabetic and non-diabetic Trinidadians

Archives of Physiology and Biochemistry

Volumn 115, Issue 1, 2009, Pages 28-33

  Nayak, Shivananda ^a   Soon, Stephanie Quan ^a   Kunjal, Ryan ^a   Ramadoo, Ria ^a   Baptiste, Okera ^a   Persad, Josann ^a   Temull, Vasant ^a   Diptee, Leon ^a   Balgobin, Sophia ^a  

^a UNIVERSITY OF THE WEST INDIES   (Trinidad and Tobago)

Author keywords

Adiponectin; Inflammatory markers; Type 2 diabetes

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ANTHROPOMETRY; ARTICLE; BLOOD; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; INFLAMMATION; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; TRINIDAD AND TOBAGO;

ADIPONECTIN; ADOLESCENT; ADULT; AGED; ANTHROPOMETRY; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; OBESITY; TRINIDAD AND TOBAGO; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 62349122699     PISSN: 13813455     EISSN: 17444160     Source Type: Journal    
DOI: 10.1080/13813450902758785     Document Type: Article

References (24)

1. Andrews E. (2004). The deadly Duo-Diabetes and obesity. Trinidad Express Newspaper, 12 July, p. 37.
2. Barcelo A, Aedo C, Rajpathali S, Robles S. (2003). The cost of diabetes mellitus in Latin America and the Caribbean. Bull World Health Organ 81(1): 9-27.
3. Daimon M, Oizumi T, Saitoh T, Kameda W, Hirata A, Yamaguchi H, Ohnuma H, Igarashi M, Kato T. (2003). Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese population. Diabetes Care 26(7): 2015-20.
4. Duncan BB, Schmidt MI, Pankow JS, Bang H, Couper D, Ballantyne CM, Hoogeveen RC, Heiss G. (2004). Adiponectin and the development of type 2 diabetes. The Atherosclerosis Risk in Communities Study. Diabetes 53(9): 2473-78.
5. Ezenwaka CE, Kalloo R, Uhlig M, Eckel J. (2004). Relationship between adiponectin and metabolic vasiables in Caribbean offspring of patients with type 2 diabetes mellitus. Horm Metab Res 36: 238-42.
6. Ezenwaka CE, Kalloo R, Uhlig M, Schwenk R, Eckel J. (2006). Serum adiponectin levels and enzyme markers of liver dys-function in diabetic and non-diabetic Caribbean subjects. Br J Biomed Sci 63: 117-22.
7. Gavrila A, Chan JL, Yiannakouris N, Kontogianni M, Miller LC, Orlova C, Mantzoros CS. (2003). Serum adiponectin levels are inversely associated with overall and central fat distri-bution but are not directly regulated by acute fasting or lep-tin administration in humans: Cross-sectional and inter-ventional studies. J Clin Endocrinol Metab 88(10): 4823-31.
8. Greenfield JR, Campbell LV. (2006). Relationship between inlam-mation, insulin resistance and type 2 diabetes: "cause or effect"? Cur Diabetes Rev 2(2): 195-211.
9. Hara K, Yamauchi T, Kadowaki T. (2005). Adiponectin: An adipokine linking adipocytes and type 2 diabetes in humans. Curr Diab Rep 5(2): 136-40.
10. Herder C, Hauner H, Haastert B, Röhrig K, Koenig W, Kolb H, Muller-Scholze S, Thorand B, Holle R, Rathmann W. (2006). Hypoadiponectinemia and proinflammatory state: Two sides of the same coin? Diabetes Care 29(7): 1626-31.
11. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. (2006). Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116(7): 1784-92.
12. King H, Aubert RE, Herman WH. (1998). Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care 21: 1414-31.
13. Krakoff J, Funahashi T, Stehouwer CDA, Schalkwijk CG, Tanaka S, Matsuzawa Y, Kobes S, Tataranni PA, Hanson RL, Knowler WC, et al. (2003). Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 26(6): 1745-51.
14. Manju Chandran SAP, Ciaraldi T, Henry RR. (2003). Adiponectin: More than just another fat cell hormone? Diabetes Care 26(8): 2442-50.
15. Obesity a research journal Inc. (2008) (updated 2007; cited June 2008). Available from: http://www.nature.com/oby/index. html
16. Obesity and type 2 diabetes Inc. (2006) (updated October 2006; cited June 2008). Available from http://diabetes.about.com/od/symptomsdiagnosis/a/obesity. htm
17. Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K. (2003). Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 14(6): 561-66.
18. Schulze MB, Rimm EB, Shai I, Rifai N, Hu FB. (2004). Relationship between adiponectin, glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. Diabetes Care 27(7): 1680-87.
19. Snehalatha C, Mukesh B, Simon M, Viswanathan V, Haffner SM, Ramachandran A. (2003). Plasma adiponectin is an independent predictor of type 2 diabetes in Asian Indians. Diabetes Care 26(12): 3226-9.
20. Spranger J, Kroke A, Möhlig M, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF. (2003). Adiponectin and protection against type 2 diabetes mellitus in Europeans. Lancet 361(9353): 226-228.
21. Tilg H, Moschen AR. (2008). Inflammatory mechanisms in the regulation of insulin resistance. Mol Med 14(3/4): 222-31.
22. Von Eynatten M, Hamann A, Twardella D, Nawroth PP, Brenner H, Rothenbacher D. (2006). Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease. Clin Chem 52(5): 853-9.
23. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, PratleyRE, Tataranni A. (2001). Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86(5): 1930-35.
24. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, Chen CL, Tai TY, Chuang LM. (2002). Plasma adiponectin levels in overweight and obese Asians. Obes Res 10(11): 1104-10.